My research program is centered on translating findings from cognitive, affective, and social neuroscience into novel interventions (e.g., mindfulness training) that effectively target transdiagnostic mechanisms underpinning stress-related, biobehavioral conditions such as addiction, chronic pain syndromes, and emotion dysregulation. I have a broad background in interdisciplinary clinical research on psychosocial interventions for stress-related conditions, with specific training and expertise in biobehavioral research methodologies.  I was trained in intervention research at the University of North Carolina at Chapel Hill, where I completed my PhD in Social Work and was awarded Ruth L. Kirschstein pre- and post-doctoral fellowships in integrative medicine from the National Institutes of Health to conduct clinical trials at the University of North Carolina at Chapel Hill School of Medicine.

Current Research Projects

Targeting Hedonic Dysregulation to Address Chronic Pain and Opioid Misuse in Primary Care (NIDA R01. PI: Garland).

Prescription opioid misuse is a public health threat that is being addressed with heightened urgency at both clinical and policy levels. In primary care settings, where chronic pain is commonly treated with long-term opioid therapy, as many as one-in-three chronic pain patients misuse opioids, evidenced by aberrant drug-related behaviors such as dose escalation or use of opioids to self-medicate negative emotions. According to a 2015 NIH-AHRQ systematic review of long-term opioid therapy for chronic pain (Chou et al., 2015), research on risk mitigation strategies for opioid misuse among chronic pain patients is virtually nonexistent. Extant therapies for opioid misuse and chronic pain may have limited efficacy because they fail to directly target the maladaptive emotion-cognition interactions and hedonic dysregulation inherent in these co-occurring problems. To meet this need, the PI developed a novel behavioral intervention, Mindfulness-Oriented Recovery Enhancement (MORE). MORE is innovative in that it aims to modify associative learning mechanisms hijacked during the allostatic process of opioid misuse by strengthening top-down cognitive control to restructure bottom-up reward learning from valuation of drug reward to natural reward – something that no other behavioral intervention for opioid misuse has been designed to do. The goal of the proposed study is to conduct a full-scale RCT of MORE to reduce aberrant drug-related behaviors and chronic pain among opioid misusing patients in primary care. Participants will be randomized to 8 weeks of MORE or a conventional support group control. Patient-reported outcomes will be assessed pre- to post-treatment and through a 9-month follow-up; this data will be triangulated through physician evaluation, urine toxicology, and medical records. Design features of this hybrid study draw upon complementary strengths of Stage II and Stage III research as defined by the NIH Stage Model (Onken et al., 2014) maximizing internal validity, intervention potency, and fidelity assurance with research therapists while maximizing external validity by administering the intervention in community clinics – the setting where the majority of chronic pain patients seek health care. The proposed project will elucidate cognitive, affective, and autonomic mechanisms mediating the therapeutic effect of MORE on aberrant drug-related behavior and pain, and will examine psychiatric and psychophysiological moderators and predictors of treatment response – including an innovative biomarker representing the relative salience of drug and natural reward. Ecological momentary assessments of pain, craving, and affective states will be correlated with opioid dosing data and therapeutic skill practice to reveal how MORE modulates symptoms and opioid misuse in everyday life. This translational research proposal from a New Investigator could significantly reshape the treatment of prescription opioid misuse among chronic pain patients by targeting top-down and bottom-up mechanisms underlying these intersecting issues and advancing evidence-based integration of behavioral health into primary care.

Targeting Co-Occurring Disorders in the Community with Mindfulness-Oriented Recovery Enhancement (DOD Clinical Trial Award. PI: Garland).

The co-occurrence of chronic pain, psychological distress, and misuse of prescription opioids undermines the mission of the U.S. Military and inflicts suffering upon Veterans and their families. Approximately one-half of service members have chronic pain following deployment, and nearly one-fifth engage in opioid misusing behaviors like unauthorized dose escalation and use of opioids to self-medicate stress and anxiety. The state of Utah (where the proposed study will be conducted) has one of the highest incidences of nonmedical use of opioids in the U.S. and a rapidly increasing rate of prescription opioid-related deaths. Indeed, an estimated 21% of Utah adults were prescribed opioids during the past year, of which approximately one-in-five report taking more than prescribed. Given that military personnel and veterans have higher rates of pain-related conditions than the general population, their risk for opioid-related problems is significantly enhanced.

New scientific findings indicate that because stress worsens pain and increases habit responses in the brain, individuals who cope with stress and pain through opioids are likely to have the most serious and difficult-to-treat opioid-related problems. The recent wars in Iraq and Afghanistan have been marked by repeated deployments involving serious combat-related and occupational stress. Unfortunately, there are no evidence-based treatments that simultaneously address pain, opioid misuse, and psychological distress. To fill this gap, this research proposal aims to conduct a pragmatic trial of a novel integrative medicine approach combining Mindfulness-Oriented Recovery Enhancement (MORE) with conventional opioid pain management for service members and Veterans. MORE aims to strengthen self-control over habit behaviors, increase flexible thinking under conditions of stress, and promote the sense of reward and meaning in the face of adversity.

This research project will help active duty service members and Veterans with chronic pain and stress who are at-risk for opioid misuse, and will also inform the treatment of civilians with similar issues. Should MORE prove to be effective in a community-based context, within two years following completion of the proposed project it could be easily transported into military installations and Veterans Administration Medical Centers in the U.S. and around the world, as well as in communities where no major military medical center is present. In these settings, MORE could be offered as a form of standard integrative health care provided to service members and Veterans.

A secondary objective of the proposed project is to utilize lab-based assessments and mobile technology to understand how MORE works to create therapeutic change, and to predict whether and when service members and Veterans are at risk for relapsing back to opioid misuse. To accomplish this objective, lab-based assessments will evaluate physiological reactivity to cues associated with past episodes of pain and opioid use, and a smartphone-based assessment will be used to evaluate opioid craving, pain, and negative mood in “the real world.” Because changes in heart rate and other physiological factors may indicate the extent to which a person’s brain has been triggered by opioid craving, this application of mind-body assessments to predict opioid misuse risk and treatment outcomes could facilitate early risk detection and penetrate denial.

The final objective of the project is to understand for whom MORE works best, to help ensure more efficient healthcare resource allocation to the service members and Veterans who need it most. The proposed project will enable health care providers to more effectively deliver low-cost treatment to prevent progression toward opioid addiction, thereby averting costly inpatient stays, discharge from active duty military service, and social, legal, and occupational problems among Veterans. Ultimately, the proposed research could significantly enhance the psychological and physical health of military personnel and Veterans by addressing the need for new integrative medicine treatment options with findings from the leading edge of science.

Mindfulness and Positive Emotion Regulation.

I am pursuing experimental research in the laboratory, as well as observational studies and clinical trials, to explore the effects of mindfulness on positive emotion regulation. Specifically, I am interested in how mindfulness and related psychological factors may influence two key positive emotional processes: positive reappraisal coping and savoring. These forms of positive emotion regulation are closely linked to mental health and well-being. Finding ways to promote these processes may be the key to ameliorating conditions that involve reward dysregulation (i.e., being unable to receive pleasure healthful objects and events in the natural environment – think smiling babies and sunsets) such as addiction and chronic negative mood states. This line of research informs my theory development efforts.

Cognitive, Affective, and Psychophysiological Mechanisms in Health and Mental Health.

I also study basic cognitive, emotional, and psychophysiological processes implicated in mental health problems and addiction. For instance, I conduct research on the attentional bias – that is, the phenomenon by which people more rapidly detect and focus on objects and events that are congruent with their current mood than those that are not congruent with their current emotional state. Thus, individuals in a negative mood state tend to pay attention to objects, persons, and events that they construe as disappointing, upsetting, or frightening, while overlooking or ignoring what is beautiful, affirming, or pleasurable. Attentional bias is particularly evident in addiction when addicts are “triggered” and find their attention automatically captured by drug-related cues (such as the sight of a cigarette, pill, or bottle of liquor) even when they want to stay clean and sober. I am also interested in studying how the brain modulates the heart beat when people are paying attention to emotional stimuli and experiences. My studies and the studies of others have shown that rapid, beat-to-beat changes in heart rate, known as heart rate variability, are significantly associated with emotional states and degree of mental focus.

Mind-Body Interventions in Supportive Oncology and Survivorship.

As Associate Director of Integrative Medicine in the Supportive Oncology and Survivorship Program of the Huntsman Cancer Institute, I conduct research on the therapeutic effects of mind-body interventions for cancer and their mechanisms of action. New research efforts are focused on mindfulness training, guided imagery, and clinical hypnosis, as well as their integration with other complementary therapies, including acupuncture, osteopathy, and exercise. This area of research is particularly fertile ground for studies on the cognitive, affective, and psychophysiological pathways linking mindfulness to positive reappraisal coping, the capacity to find meaning and purpose in the face of adversity.

Research Conflict of Interest Disclosure

Eric Garland, PhD, LCSW is the Director of the Center on Mindfulness and Integrative Health Intervention Development. The Center provides Mindfulness-Oriented Recovery Enhancement (MORE), mindfulness-based therapy, and cognitive behavioral therapy in the context of research trials for no cost to research participants; however, Dr. Garland has received honoraria and payment for delivering seminars, lectures, and teaching engagements (related to training clinicians in MORE), including those sponsored by institutions of higher education, government agencies, academic teaching hospitals, and medical centers. Dr. Garland also receives royalties from the sale of books related to MORE. Dr. Garland has also been a consultant and licensor to BehaVR, LLC.